Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial - PubMed
3 hours ago
- #psoriatic arthritis
- #obesity management
- #clinical trial
- Combined ixekizumab and tirzepatide treatment led to greater weight reduction and arthritis control in psoriatic arthritis patients with overweight or obesity compared to ixekizumab alone.
- The primary endpoint of achieving both ACR50 and ≥10% weight reduction at 36 weeks was met by 31.7% in the combination group versus 0.8% in the monotherapy group.
- Significant improvements were observed in multiple secondary outcomes, including ACR50, ACR20, minimal disease activity, and patient-reported quality of life measures.
- Safety profiles for both treatments were consistent with previous studies, with no new safety concerns identified.
- The study supports the potential of dual therapy to address both inflammatory and metabolic aspects of psoriatic arthritis in affected individuals.